Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

The interplay of structure and dynamics: insights from a survey of HIV-1 reverse transcriptase crystal structures.

Seckler JM, Leioatts N, Miao H, Grossfield A.

Proteins. 2013 Oct;81(10):1792-801. doi: 10.1002/prot.24325. Epub 2013 Aug 16.

2.

Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors.

Ren J, Nichols C, Bird L, Chamberlain P, Weaver K, Short S, Stuart DI, Stammers DK.

J Mol Biol. 2001 Sep 28;312(4):795-805.

PMID:
11575933
3.

The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance.

Hsiou Y, Ding J, Das K, Clark AD Jr, Boyer PL, Lewi P, Janssen PA, Kleim JP, Rösner M, Hughes SH, Arnold E.

J Mol Biol. 2001 Jun 1;309(2):437-45.

PMID:
11371163
4.

Crystal structures of HIV-1 reverse transcriptases mutated at codons 100, 106 and 108 and mechanisms of resistance to non-nucleoside inhibitors.

Ren J, Nichols CE, Chamberlain PP, Weaver KL, Short SA, Stammers DK.

J Mol Biol. 2004 Feb 20;336(3):569-78.

PMID:
15095972
5.

Structural insights into mechanisms of non-nucleoside drug resistance for HIV-1 reverse transcriptases mutated at codons 101 or 138.

Ren J, Nichols CE, Stamp A, Chamberlain PP, Ferris R, Weaver KL, Short SA, Stammers DK.

FEBS J. 2006 Aug;273(16):3850-60.

6.

HIV-1 reverse transcriptase (RT) polymorphism 172K suppresses the effect of clinically relevant drug resistance mutations to both nucleoside and non-nucleoside RT inhibitors.

Hachiya A, Marchand B, Kirby KA, Michailidis E, Tu X, Palczewski K, Ong YT, Li Z, Griffin DT, Schuckmann MM, Tanuma J, Oka S, Singh K, Kodama EN, Sarafianos SG.

J Biol Chem. 2012 Aug 24;287(35):29988-99. doi: 10.1074/jbc.M112.351551. Epub 2012 Jul 2.

7.

Effect of a bound non-nucleoside RT inhibitor on the dynamics of wild-type and mutant HIV-1 reverse transcriptase.

Zhou Z, Madrid M, Evanseck JD, Madura JD.

J Am Chem Soc. 2005 Dec 14;127(49):17253-60.

PMID:
16332074
8.

Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097.

Das K, Sarafianos SG, Clark AD Jr, Boyer PL, Hughes SH, Arnold E.

J Mol Biol. 2007 Jan 5;365(1):77-89. Epub 2006 Sep 15.

PMID:
17056061
9.

3'-Azido-3'-deoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can induce long range conformational changes.

Ren J, Esnouf RM, Hopkins AL, Jones EY, Kirby I, Keeling J, Ross CK, Larder BA, Stuart DI, Stammers DK.

Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9518-23.

10.

Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase.

Ren J, Milton J, Weaver KL, Short SA, Stuart DI, Stammers DK.

Structure. 2000 Oct 15;8(10):1089-94.

11.

HIV-1 reverse transcriptase and antiviral drug resistance. Part 2.

Das K, Arnold E.

Curr Opin Virol. 2013 Apr;3(2):119-28. doi: 10.1016/j.coviro.2013.03.014. Epub 2013 Apr 19. Review.

13.

HIV-1 reverse transcriptase and antiviral drug resistance. Part 1.

Das K, Arnold E.

Curr Opin Virol. 2013 Apr;3(2):111-8. doi: 10.1016/j.coviro.2013.03.012. Epub 2013 Apr 19. Review.

14.

Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.

Hopkins AL, Ren J, Milton J, Hazen RJ, Chan JH, Stuart DI, Stammers DK.

J Med Chem. 2004 Nov 18;47(24):5912-22.

PMID:
15537346
15.

Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance.

Tantillo C, Ding J, Jacobo-Molina A, Nanni RG, Boyer PL, Hughes SH, Pauwels R, Andries K, Janssen PA, Arnold E.

J Mol Biol. 1994 Oct 28;243(3):369-87. Review.

PMID:
7525966
16.
17.

Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant.

Das K, Ding J, Hsiou Y, Clark AD Jr, Moereels H, Koymans L, Andries K, Pauwels R, Janssen PA, Boyer PL, Clark P, Smith RH Jr, Kroeger Smith MB, Michejda CJ, Hughes SH, Arnold E.

J Mol Biol. 1996 Dec 20;264(5):1085-100.

PMID:
9000632
18.

An in-silico approach aimed to clarify the role of Y181C and K103N HIV-1 reverse transcriptase mutations versus Indole Aryl Sulphones.

Massarotti A, Coluccia A.

J Mol Graph Model. 2016 Jan;63:49-56. doi: 10.1016/j.jmgm.2015.11.013. Epub 2015 Nov 25.

PMID:
26650686
19.

Docking, molecular dynamics and quantitative structure-activity relationship studies for HEPTs and DABOs as HIV-1 reverse transcriptase inhibitors.

Mao Y, Li Y, Hao M, Zhang S, Ai C.

J Mol Model. 2012 May;18(5):2185-98. doi: 10.1007/s00894-011-1236-8. Epub 2011 Sep 27.

PMID:
21947448
20.

Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.

Freeman GA, Andrews Iii CW 3rd, Hopkins AL, Lowell GS, Schaller LT, Cowan JR, Gonzales SS, Koszalka GW, Hazen RJ, Boone LR, Ferris RG, Creech KL, Roberts GB, Short SA, Weaver K, Reynolds DJ, Milton J, Ren J, Stuart DI, Stammers DK, Chan JH.

J Med Chem. 2004 Nov 18;47(24):5923-36.

PMID:
15537347

Supplemental Content

Support Center